Title : Enasidenib and ivosidenib in AML.

Pub. Date : 2020 Oct

PMID : 32955829






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Enasidenib and ivosidenib are potent and selective inhibitors of mutant IDH2 and IDH1, respectively, act as differentiating agents and showed clinical activity in relapse/refractory (R/R) AML harboring the specific mutation. enasidenib isocitrate dehydrogenase (NADP(+)) 1 Homo sapiens